For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
FOXO4-DRI (also called Proxofim) is a 26-amino-acid cell-penetrating D-retro-inverso peptide designed to disrupt the FOXO4-p53 protein-protein interaction that keeps senescent cells alive. Published in Cell in 2017 by Baar et al. at Erasmus University Medical Center, it represents the first peptide-based senolytic: a compound that selectively induces apoptosis in senescent cells while sparing healthy tissue. In mouse studies, it reversed chemotoxicity from doxorubicin, restored fur density and fitness in fast-aging and naturally aged mice, and improved renal function. The mechanism has been structurally characterized by NMR in a 2025 Nature Communications paper. No human clinical trial has been published. Cleara Biotech, formed to commercialize the original work, has moved beyond FOXO4-DRI itself to develop optimized derivatives CL04177 and CL04183 now in pre-IND/IMPD studies. Widespread human self-experimentation with commercially available FOXO4-DRI is occurring without safety or efficacy data.
FOXO4-DRI has no published human clinical trial data of any kind. No Phase 1 safety study, no human pharmacokinetic data, no dose-escalation study, and no efficacy signal in humans. Every published study is either in vitro, ex vivo, or in mouse models. The compound is at the preclinical stage by any evidentiary standard, despite being commercially available from multiple research vendors and widely self-administered by the biohacking community.
The D-retro-inverso (DRI) modification is a key chemical feature. By using all D-amino acids in the reverse sequence, FOXO4-DRI is highly resistant to protease degradation compared to standard L-amino acid peptides. This is pharmacologically advantageous (it survives in vivo conditions better than most peptides) but also means less is known about its metabolism, clearance, and distribution in human tissue, since the DRI modification is rarely encountered in approved therapeutics.
A critical safety concern is the potential for non-selective apoptosis. The selectivity argument, that FOXO4 is expressed almost exclusively in senescent cells and that FOXO4-DRI therefore spares healthy tissue, is supported in the original mouse studies and in limited in vitro work. However, the Baar 2017 paper tested selectivity in a limited set of cell types (primarily IMR90 fibroblasts with radiation-induced senescence and some hepatocytes). Senescent cells are highly heterogeneous across tissues, and not all forms of senescence rely equally on the FOXO4-p53 axis. Off-target apoptosis in healthy cells expressing low but non-zero FOXO4 levels, particularly at the doses being self-administered (often 5 mg/kg by extrapolation from mouse data), has not been ruled out in human tissue.
A naming note: the compound is sometimes called Proxofim in some literature and vendor contexts. This refers to the same FOXO4-DRI structure from the Baar 2017 paper.
The company Cleara Biotech (Rotterdam, Netherlands), founded by Dr. Patrick de Keizer (lead author of the 2017 Cell paper), has pivoted its clinical development focus to optimized second and third generation compounds (CL04177 and CL04183) rather than FOXO4-DRI itself. As of 2024 to 2025, Cleara is conducting pre-IND/IMPD preparation studies for CL04183. This means the original FOXO4-DRI is not the compound being taken toward clinical approval by the institution best positioned to do so.
Cellular senescence is a state in which cells permanently halt division in response to damage, telomere shortening, or oncogenic stress. Senescent cells do not die, however; they persist in tissues and secrete a mixture of inflammatory cytokines, proteases, and growth factors collectively called the senescence-associated secretory phenotype (SASP). While senescence is beneficial in certain contexts (wound healing, embryonic development, tumor suppression), the accumulation of senescent cells with age drives chronic low-grade inflammation and contributes to multiple age-related pathologies including tissue dysfunction, cardiovascular disease, neurodegeneration, and cancer progression.
FOXO4-DRI was developed by Baar et al. at Erasmus University Medical Center, Rotterdam, and published in Cell in March 2017. The discovery originated from RNA sequencing of senescent versus normal human IMR90 fibroblasts, which revealed that senescent cells are paradoxically primed for apoptosis (elevated PUMA and BIM, reduced BCL-2) yet resist dying. The search for the mechanism that suppresses this latent apoptotic potential led to FOXO4, a member of the Forkhead box transcription factor family. FOXO4 expression is markedly increased in senescent cells, and it physically interacts with p53 within nuclear bodies adjacent to DNA damage foci, sequestering p53 and preventing it from executing its apoptotic function.
FOXO4-DRI was designed using the D-retro-inverso strategy: the peptide sequence corresponds to the FOXO4 domain that interacts with p53, but composed entirely of D-amino acids in reversed sequence. This modification makes the peptide resistant to protease degradation while retaining the ability to bind p53 and compete with endogenous FOXO4. As a cell-penetrating peptide, FOXO4-DRI enters cells and disrupts the FOXO4-p53 interaction. In senescent cells, this releases p53 from nuclear sequestration, allowing it to translocate to mitochondria and trigger cytochrome C release and caspase-dependent apoptosis. In non-senescent cells lacking the elevated FOXO4-p53 interaction, FOXO4-DRI has little effect.
The 2017 Cell paper represents a milestone because it was the first demonstration of a peptide-based senolytic with both in vitro selectivity and in vivo functional outcomes in aging models. Previous senolytics, primarily the dasatinib-quercetin combination and navitoclax/ABT-263/ABT-737, worked through BCL-2/BCL-XL inhibition and were associated with significant toxicity (particularly thrombocytopenia with navitoclax). FOXO4-DRI targeted a different mechanism and appeared to avoid these toxicities in mice, though the critical qualification is that only mouse data exist.
Cleara Biotech was founded on the scientific foundation of the 2017 paper. It has since developed optimized derivatives with enhanced binding to phosphorylated p53 (the "scarred" p53 form elevated in stressed senescent and cancer cells). As of 2024 to 2025, their lead clinical candidate CL04183 is in pre-IND/IMPD preparation, focused on oncology indications involving mutant-p53 cancers rather than aging per se.
FOXO4-DRI operates through a precisely characterized protein-protein interaction disruption mechanism. The molecular basis was fully resolved by NMR structural analysis published in Nature Communications in 2025 (Sickmeier et al.).
In senescent cells, FOXO4 protein is highly expressed and localizes to promyelocytic leukemia (PML) nuclear bodies that are adjacent to 53BP1-containing DNA-SCARS (DNA Segments with Chromatin Alterations Reinforcing Senescence). Within these nuclear structures, FOXO4 physically binds to p53 and sequesters it, preventing p53 from executing its pro-apoptotic function. This FOXO4-p53 interaction is the specific survival mechanism that keeps senescent cells alive despite their paradoxical upregulation of pro-apoptotic proteins (PUMA, BIM) and downregulation of anti-apoptotic BCL-2.
FOXO4-DRI is designed to mimic the p53-binding domain of FOXO4 using the D-retro-inverso configuration: the sequence of D-amino acids in reverse corresponds to the active FOXO4 p53-interacting region. The 2025 Nature Communications NMR study revealed that FOXO4-DRI binds the disordered p53 transactivation domain 2 (TAD2), forming a transiently folded complex. This interaction is enhanced by p53 phosphorylation, meaning FOXO4-DRI binds more strongly to the stressed, activated p53 found in senescent and cancer cells. Both the FOXO4-derived peptide region and the cationic cell-permeability component contribute to the p53 binding interaction.
When FOXO4-DRI enters a senescent cell and displaces FOXO4 from p53, the newly liberated p53 undergoes nuclear exclusion and translocates to mitochondria. This mitochondrial translocation of p53 is a transcription-independent apoptotic signal: p53 at mitochondria triggers BAX/BAK-dependent cytochrome C release and caspase-3 cleavage, executing apoptosis. The entire process is caspase-dependent (pan-caspase inhibitors block FOXO4-DRI-induced death) and p53-dependent (p53 knockdown abolishes selectivity).
In non-senescent cells, FOXO4 expression is low and the FOXO4-p53 nuclear sequestration does not operate at the same magnitude. FOXO4-DRI therefore has little to bind and minimal apoptotic effect. This selectivity has been demonstrated in IMR90 fibroblasts (radiation-induced senescence), H2O2-induced senescent Leydig cells, replicatively senescent chondrocytes, and murine hepatocytes. The caveat is that FOXO4 expression is not zero in non-senescent adult cells; some low-level expression exists in specific tissue types, and the degree of selectivity in all human tissues at therapeutically relevant doses has not been characterized.
The DRI (D-retro-inverso) modification gives FOXO4-DRI exceptional stability. Standard L-amino acid peptides are rapidly cleaved by serine proteases and metallopeptidases in blood and tissue. The all-D configuration creates a mirror-image backbone that is not recognized by these enzymes, dramatically extending the peptide's biological half-life compared to the natural L-amino acid version. This stability is a pharmacological advantage for achieving tissue distribution but also means FOXO4-DRI persists longer in the body than typical peptides, with implications for potential cumulative effects.
The Baar 2017 Cell paper established the proof-of-concept for peptide senolysis in three mouse models. In the chemotoxicity model, doxorubicin treatment reduced body weight and increased hepatic IL-6, plasma AST (liver damage marker), and hepatic FOXO4 foci. FOXO4-DRI reversed each of these effects, normalizing body weight, liver enzyme levels, and inflammatory markers.
In fast-aging XpdTTD/TTD mice (a progeroid model of accelerated aging), FOXO4-DRI treatment restored fur density, improved exploratory behavior, and restored voluntary running wheel activity compared to vehicle controls. These mice model a syndrome of premature aging with features including hair loss, ataxia, and organ dysfunction.
In naturally aged wild-type mice (112 to 125 weeks old), FOXO4-DRI restored fur density and fitness comparably to what was observed in fast-aging mice. Kidney function was specifically examined: aged mice showed increased plasma urea and elevated renal tubular IL-6 expression. FOXO4-DRI increased TUNEL positivity (apoptosis marker) in aged renal tubular cells and normalized kidney function parameters.
Throughout all three models, FOXO4-DRI was described as well-tolerated. Specifically, it did not cause the thrombocytopenia (platelet reduction) that limits navitoclax, a BCL-2 family inhibitor with senolytic activity. This safety differential was cited as a key advantage.
The commentary accompanying the paper in Cell (de Keizer, 2017, "The Fountain of Youth by Targeting Senescent Cells?") contextualized the finding: FOXO4-DRI targets a mechanism specific to senescent cells with fewer expected off-target effects than broad BCL-2 inhibitors, but emphasized that much more work was required before human application could be contemplated.
The 2017 Cell paper is a landmark in senolytic research. The three mouse models, chemotoxicity, progeroid, and natural aging, provide a convergent functional case for senescent cell clearance restoring tissue homeostasis. The absence of thrombocytopenia separates FOXO4-DRI mechanistically from navitoclax. All data are in mice; the translational gap to humans is substantial and has not been bridged in the 8-plus years since publication.
The 2025 Nature Communications NMR study solved an important structural puzzle: how does a disordered peptide (FOXO4-DRI) interact with a disordered protein domain (p53 TAD2)? Unexpectedly, the disordered FOXO4-DRI binds the disordered p53TAD2 and forms a transiently folded complex. This is a rare example of disorder-to-order folding triggered by two intrinsically disordered binding partners.
Key mechanistic findings: (1) Both the FOXO4-derived sequence and the cationic cell-permeability component of FOXO4-DRI contribute to p53 binding. The original assumption was that only the FOXO4-mimicking portion drove binding; the NMR data show the permeability tag also participates. (2) p53 phosphorylation at specific residues significantly enhances affinity for both FOXO4 and FOXO4-DRI. This explains why FOXO4-DRI has preferential activity in stressed and senescent cells where p53 phosphorylation is elevated, and provides the mechanistic basis for the "scarred p53" concept that Cleara Biotech uses to define its optimized derivatives.
The 2025 paper also reports that optimization of FOXO4-DRI based on this structural understanding has led to two compounds currently in preclinical development for oncology (patent applications WO/2023/180570 and WO/2021/165538), though these are Cleara Biotech compounds CL04177/CL04183, not FOXO4-DRI itself.
The NMR structural data resolve the mechanism at atomic resolution and provide a rational framework for drug development beyond FOXO4-DRI. The original IMR90 fibroblast studies established in vitro selectivity: FOXO4-DRI reduced viability only in senescent fibroblasts (generated by ionizing radiation or doxorubicin), not in proliferating controls. P53 knockdown and pan-caspase inhibition both blocked FOXO4-DRI's senolytic activity, confirming p53 and caspase dependence.
The 2025 NMR study is the definitive mechanistic characterization of FOXO4-DRI. The disorder-to-order complex formation with p53TAD2 is scientifically unusual and provides a rational basis for understanding both selectivity (phospho-p53 enriched in stressed cells) and for designing improved derivatives. This mechanism work is well-validated; the gap is translation from in vitro mechanism to human efficacy, which remains entirely unaddressed.
The Leydig cell study (Zhang et al. 2020, Aging) extended FOXO4-DRI from the original fibroblast model to a specific clinical context: male late-onset hypogonadism driven by senescent Leydig cells. FOXO4 was found to be expressed in human Leydig cells, and nuclear translocation increased with age. In senescent TM3 Leydig cells (H2O2-induced), FOXO4-DRI caused p53 nuclear exclusion and selective apoptosis, with minimal effect on non-senescent Leydig cells. In naturally aged mice, FOXO4-DRI improved the testicular microenvironment and alleviated age-related testosterone insufficiency.
The chondrocyte study (Cheng et al. 2021, Frontiers in Bioengineering) tested FOXO4-DRI in a clinically relevant cell manufacturing context: chondrocytes expanded in vitro to population doubling level 9 (PDL9) for autologous chondrocyte implantation accumulate senescent cells. FOXO4-DRI removed more than 50% of cells from PDL9 chondrocytes without significantly affecting PDL3 (early-passage, non-senescent) chondrocytes. Senescence markers (SA-beta-gal, p16, p21, p53) were reduced. However, the chondrogenic potential of FOXO4-DRI-pretreated PDL9 cells was not enhanced in standard pellet culture. Cartilage tissue from pretreated cells showed lower expression of SASP factors. The finding that FOXO4-DRI removes senescent cells but does not improve chondrogenic output is a functionally negative result for the ACI application, even though the senolytic activity itself was confirmed.
The 2024 vascular endothelial study in naturally aged and progeroid mice showed FOXO4-DRI improved aortic function and reduced endothelial cell senescence through p53/BCL-2/Caspase-3 pathway activation. The study used co-immunoprecipitation to confirm FOXO4-DRI prevents FOXO4 binding to p53 in this cell type.
These tissue-specific studies demonstrate that FOXO4-DRI's senolytic activity extends across multiple cell types (fibroblasts, Leydig cells, chondrocytes, endothelial cells), consistent with the mechanism being broadly applicable wherever the FOXO4-p53 survival axis operates. The chondrocyte study's negative functional result (senolysis confirmed but chondrogenic output not improved) is an important cautionary finding: senescent cell clearance does not automatically produce the expected downstream functional benefit. All studies are preclinical.
The chemotoxicity reversal in the 2017 Cell paper established one of FOXO4-DRI's most clinically motivated applications: mitigating the long-term consequences of cancer chemotherapy. Doxorubicin (and other chemotherapeutics) induces senescence in non-cancer bystander cells throughout the body, and this therapy-induced senescence contributes to the long-term side effects of chemotherapy including organ dysfunction, fatigue, and accelerated aging. FOXO4-DRI reversed doxorubicin-induced weight loss, normalized plasma AST (liver damage marker), and reduced hepatic IL-6 expression, suggesting clearance of therapy-induced senescent hepatocytes.
The 2021 EBioMedicine paper by Domen et al. took a different approach, using FOXO4-DRI as a reference compound to benchmark new rationally designed senolytic peptides. The comparison showed that novel peptides (ES1, ES2) had 3 to 7-fold higher senolytic activity than FOXO4-DRI in the selectivity index between dividing and senescent cells. This is a mixed finding for FOXO4-DRI: it confirms the compound has genuine senolytic activity, but positions it as a first-generation benchmark rather than an optimized drug candidate. The improved peptides demonstrated activity against orthotopic melanoma when delivered intratumorally with a Braf inhibitor.
The cancer-adjacent application is important context for Cleara Biotech's clinical development strategy: CL04183, their lead candidate, is specifically targeted at mutant-p53 metastatic cancer rather than aging per se, exploiting the enhanced binding of optimized compounds to phosphorylated ("scarred") p53 in cancer cells.
The chemotherapy senescence reversal data are mechanistically compelling and clinically motivated. The Domen 2021 data confirming FOXO4-DRI's senolytic activity while demonstrating that newer peptides outperform it is useful context: FOXO4-DRI works, but it is not the optimized version of the pharmacophore. The cancer application (Cleara's clinical focus) is distinct from the aging application (what biohackers self-administer it for). Both applications remain at the preclinical stage.
FOXO4-DRI has been commercially available from research peptide vendors since approximately 2018, and its accessibility has generated a substantial biohacking self-experimentation community. Participants typically translate the mouse intraperitoneal dose (5 mg/kg in mice) to an approximate human dose using body surface area scaling, arriving at estimates of 0.3 to 0.5 mg/kg or roughly 20 to 50 mg per human injection, administered subcutaneously across 3 doses on alternating days. Anecdotal reports describe various subjective experiences including improved energy, skin changes, and soreness, but none of these are controlled observations.
The critical problems with self-experimentation data:
No baseline senescent cell burden measurement exists before or after treatment (no validated serum or tissue biomarker for senescent cell load is available for self-experiment use). Without this, it is impossible to know whether FOXO4-DRI actually reduced senescent cells in any individual.
No objective functional assessments (grip strength, VO2 max, kidney function, liver enzymes) are standardly measured in self-experiments.
The route of administration (subcutaneous injection vs. the mouse intraperitoneal route) affects pharmacokinetics. IP injection in mice delivers compound directly to the peritoneum and achieves different tissue distribution than subcutaneous injection in a human.
The dose scaling assumptions (using body surface area rather than mg per unit body weight) introduce a 10-fold dose reduction compared to direct mg/kg extrapolation. It is unclear which scaling approach is appropriate.
No reported serious adverse events have been published or described in accessible community forums as of early 2026. This absence of reported harm is not evidence of safety.
The Fight Aging! blog, which closely tracks the biohacker community, explicitly noted in February 2026 that widespread self-experimentation with FOXO4-DRI has produced "no useful data."
The fundamental problem with self-experimentation for a senolytic: the expected benefit (reduced senescent cell burden, improved long-term health) manifests over months to years, not days to weeks. The acute subjective experiences described in self-experiment reports are more likely placebo effects or injection-site inflammation than genuine senolytic outcomes.
The self-experimentation with FOXO4-DRI is occurring on a meaningful scale but has produced zero useful scientific data. There is no validated biomarker to measure the target (senescent cell clearance) in self-experiment settings. The absence of acute serious adverse events is weakly reassuring but does not characterize long-term risk. Self-experimenters are, without knowing it, taking doses of an uncharacterized compound that disrupts p53-mediated apoptosis pathways with no monitoring of organ function, immune status, or the very senescent cell load that is the supposed therapeutic target.
Senolytic peptide. Weight-based 0.1mg/kg in mice. No human data.
No human pharmacokinetic, dose-finding, or safety data exist for FOXO4-DRI. The doses shown (1 to 10 mg) represent the range of community extrapolations from mouse studies using body surface area scaling factors. The only validated experimental dose is 5 mg/kg IP in mice. D-retro-inverso peptides have substantially different pharmacokinetics from standard L-amino acid peptides due to protease resistance; human half-life, tissue distribution, and clearance are entirely unknown. Cleara Biotech is pursuing pre-IND/IMPD studies for optimized derivatives (CL04177/CL04183), not FOXO4-DRI, suggesting the original compound will not generate human PK data through formal clinical development.
Within the senolytic field, FOXO4-DRI occupies a specific niche: the first peptide-based senolytic with in vivo proof-of-concept, and the compound that initiated a wave of academic and commercial interest in targeting the FOXO4-p53 axis. The main competing senolytic approach is dasatinib plus quercetin (D+Q), which has undergone Phase 2 human trials across multiple indications with mixed results. Navitoclax (ABT-263), a BCL-2/BCL-XL inhibitor with demonstrated senolytic activity, causes dose-limiting thrombocytopenia that FOXO4-DRI appears to avoid, but navitoclax has advanced further in clinical development for hematologic malignancies. The key structural difference between FOXO4-DRI and D+Q is mechanistic precision: FOXO4-DRI targets a specific protein-protein interaction elevated in senescent cells, while D+Q targets broader anti-apoptotic pathways with more off-target effects. Whether this mechanistic precision translates to better human safety or efficacy remains to be demonstrated. In the biohacking community, FOXO4-DRI is often discussed alongside Epithalon and other anti-aging peptides, but it operates through a fundamentally different mechanism: Epithalon and related bioregulators modulate gene expression through chromatin interactions, while FOXO4-DRI directly induces apoptosis in specific cell populations. These are not comparable classes of intervention.
FOXO4-DRI has no human safety data. No human has received this compound in a controlled clinical or research setting with safety monitoring. Everything in this section derives from animal studies.
In the Baar 2017 mouse studies, FOXO4-DRI at 5 mg/kg intraperitoneally on alternating days for 3 doses was described as well-tolerated in chemotoxicity, fast-aging (XpdTTD/TTD), and naturally aged wild-type mice. No acute toxicity, significant weight loss, or organ damage was reported. Specifically, FOXO4-DRI did not produce the thrombocytopenia that is a serious and dose-limiting toxicity of navitoclax/ABT-263, the BCL-2 family senolytic. This was highlighted as a specific safety advantage in the original paper and accompanying Cell commentary.
Three theoretical safety concerns merit attention for any future human use:
Selectivity: The claim that FOXO4-DRI kills only senescent cells rests on the elevated FOXO4-p53 interaction in senescence. In the original paper, testing was performed primarily in irradiation-induced senescent IMR90 fibroblasts and in hepatocyte-enriched models. Different types of senescence (replicative, oncogene-induced, stress-induced, therapy-induced) may not all have equivalent FOXO4-p53 dependency. Off-target apoptosis in tissues with low but non-negligible FOXO4 expression (certain immune cell subtypes, liver cells in stressed states) has not been systematically ruled out at human-equivalent doses.
Beneficial senescence disruption: Senescent cells are not uniformly harmful. They play important roles in wound healing, tissue repair, and tumor suppression. Ablating senescent cells in the context of active tissue repair or injury might impair recovery. The timing question, specifically when senescent cell clearance is beneficial versus harmful, has not been resolved.
D-amino acid immunogenicity: All-D-amino acid peptides are a relatively novel class with limited long-term exposure data in humans. The immune system's response to prolonged exposure to non-proteolyzable D-amino acid sequences is not fully characterized.
Self-experimentation context: Multiple biohackers have self-administered FOXO4-DRI at doses extrapolated from mouse pharmacology (5 mg/kg in mice translating to approximately 0.4 to 1 mg/kg in humans by body surface area conversion, or roughly 25 to 75 mg per person). These self-experiments are unmonitored, unpublished, and cannot contribute to safety knowledge. They carry real risk of unknown adverse effects with no institutional oversight.
FOXO4-DRI is scientifically important and clinically premature. Those two facts coexist without contradiction.
The 2017 Cell paper is a genuine milestone. It identified the FOXO4-p53 axis as a specific survival mechanism of senescent cells, designed a peptide to disrupt it, showed selective killing of senescent cells in vitro, and demonstrated functional improvement in three mouse aging models without the thrombocytopenia toxicity of BCL-2 inhibitor senolytics. The 2025 NMR structural characterization resolved the atomic mechanism and explained the basis for selectivity. The compound works as a senolytic in the experimental systems tested.
What has not happened in 8-plus years: no human clinical trial. The compound that demonstrated the most visually striking results (restoration of fur density and physical function in aged mice) has not moved toward human testing through the company formed specifically to commercialize it. Cleara Biotech, instead, has focused on second and third generation derivatives (CL04177, CL04183) with optimized p53 binding, which are now in pre-IND/IMPD preparation. This transition is scientifically rational: the optimized compounds have better pharmacological properties. But it means FOXO4-DRI itself is unlikely to be the compound that reaches human trials.
The biohacker self-experimentation community has conducted human self-experiments with FOXO4-DRI for years without producing any useful scientific data. There is no validated biomarker to confirm senescent cell clearance, no standardized objective endpoint, and no comparison group. The self-experiments have not documented serious acute harm, but that is an insufficient basis for reassurance about a compound that disrupts p53-mediated apoptosis pathways in the human body at pharmacologically active doses.
The broader senolytic field offers additional context: dasatinib-quercetin, the most clinically developed senolytic approach, has undergone Phase 2 trials in diabetic kidney disease, pulmonary fibrosis, Alzheimer's disease, and musculoskeletal frailty. These trials have produced mixed results, with some functional improvements but also safety signals. The senolytic hypothesis in humans is not yet validated even for the most tested approach. FOXO4-DRI awaits even first-in-human data.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use